Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allergies
Recent findings in allergies described by researchers from University of Manitoba
November 26th, 2008
"Recent studies indicate that pharmaceutical blockade of phosphoinositide 3-kinase (PI3K) signaling enzymes might be effective in reducing allergic airway inflammation. Signals generated by the p110 delta PI3K isoform play critical roles in signaling through antigen and cytokine receptors and were shown to be required for induction of type 2, but not type 1, cytokine responses," researchers in Winnipeg, Canada report. "We sought to determine the effect of genetic or pharmaceutical inactivation of p110 delta PI3K on induction of IgE responses. We determined the effect of p110 delta inactivation on induction of systemic IgE responses and on the ability of purified B...
Source: Immunotherapy Weekly (2008-11-26)
|
